Citations

Citations to this article as recorded by  

• Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
  Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaali, John Prudente, Nosratola D. Vaziri, Bhupinder Singh, Wei Ling Lau
  Pharmacology Research & Perspectives.2023;[Epub]     CrossRef
• Type 2 Diabetes Mellitus: Pathogenic Features and Experimental Models in Rodents
  Inessa G. Gvazava, M. V. Karimova, A. V. Vasiliev, E. A. Vorotelyak
  Acta Naturae.2022; 14(3): 57.     CrossRef
• Role of mineralocorticoid receptor antagonists in kidney diseases
  Vishal Patel, Amit Joharapurkar, Mukul Jain
  Drug Development Research.2021; 82(3): 341.     CrossRef
• Multi-strain probiotic supplement attenuates streptozotocin-induced type-2 diabetes by reducing inflammation and β-cell death in rats
  Pei-Shan Hsieh, Hsieh-Hsun Ho, Shu Ping Tsao, Shih-Hung Hsieh, Wen-Yang Lin, Jui-Fen Chen, Yi-Wei Kuo, Shin-Yu Tsai, Hui-Yu Huang, Michael W. Greene
  PLOS ONE.2021; 16(6): e0251646.     CrossRef
• Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin
  Indira Purushothaman, Ian S. Zagon, Joseph W. Sassani, Patricia J. McLaughlin
  Biochemical Pharmacology.2021; 192: 114712.     CrossRef
• Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
  Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats
  Devesh Aggarwal, Gaaminepreet Singh
  Naunyn-Schmiedeberg's Archives of Pharmacology.2020; 393(4): 615.     CrossRef
• Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model
  Shih-Chun Yang, Ching-Yun Hsu, Wei-Ling Chou, Jia-You Fang, Shih-Yi Chuang
  Molecules.2020; 25(23): 5713.     CrossRef
• Losartan improves renal function and pathology in obese ZSF-1 rats
  Zhi Su, Deborah Widomski, Arthur Nikkel, Laura Leys, Marian Namovic, Diana Donnelly-Roberts, Murali Gopalakrishnan, Steve McGaraughty
  Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(3): 281.     CrossRef
• Analyzing polymeric nanofibrous scaffold performances in diabetic animal models for translational chronic wound healing research
  Nowsheen Goonoo, Archana Bhaw-Luximon
  Nanotechnology Reviews.2017; 6(6): 583.     CrossRef
• Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy
  Motonobu Nakamura, Nobuhiko Satoh, Masashi Suzuki, Haruki Kume, Yukio Homma, George Seki, Shoko Horita
  Biochemical and Biophysical Research Communications.2015; 461(1): 154.     CrossRef
• Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats
  Amal Hofni, Mohamed A. El-Moselhy, Ashraf Taye, Mohamed M. Khalifa
  European Journal of Pharmacology.2014; 744: 173.     CrossRef
• Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats
  Jia-sheng Wu, Rong Shi, Jie Zhong, Xiong Lu, Bing-liang Ma, Tian-ming Wang, Bin Zan, Yue-ming Ma, Neng-neng Cheng, Fu-rong Qiu
  Evidence-Based Complementary and Alternative Medicine.2013; 2013: 1.     CrossRef
• The use of animal models in diabetes research
  Aileen JF King
  British Journal of Pharmacology.2012; 166(3): 877.     CrossRef
• Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
  Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
  Diabetes & Metabolism Journal.2012; 36(2): 128.     CrossRef